Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
Kyriakie SarafoglouChris N BarnesMichael HuangErik Allen ImelIvy-Joan MaduDeborah P MerkeDavid MoriartySamer NakhleRon S NewfieldMaria G VogiatziRichard J AuchusPublished in: The Journal of clinical endocrinology and metabolism (2021)
For patients with 21OHD, up to 12 weeks of oral tildacerfont reduced or maintained key hormone biomarkers toward normal.
Keyphrases